StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS - Free Report) in a research report report published on Thursday morning. The firm issued a sell rating on the biotechnology company's stock.
Separately, Barclays decreased their price objective on shares of Cellectis from $7.00 to $5.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 5th.
View Our Latest Stock Analysis on CLLS
Cellectis Price Performance
Cellectis stock traded down $0.04 during trading on Thursday, hitting $1.87. The stock had a trading volume of 47,438 shares, compared to its average volume of 50,723. The stock's 50 day moving average is $1.99 and its two-hundred day moving average is $2.22. Cellectis has a 1 year low of $1.70 and a 1 year high of $3.77. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78.
Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The business had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. During the same period last year, the business posted ($0.31) earnings per share. Analysts predict that Cellectis will post -0.46 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Cellectis
Several institutional investors have recently bought and sold shares of the stock. First Affirmative Financial Network bought a new position in Cellectis in the 3rd quarter worth $45,000. Long Focus Capital Management LLC lifted its stake in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock worth $8,634,000 after buying an additional 130,000 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Cellectis during the second quarter valued at approximately $29,000. Finally, Principal Financial Group Inc. raised its holdings in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company's stock worth $817,000 after acquiring an additional 12,467 shares during the last quarter. 63.90% of the stock is currently owned by hedge funds and other institutional investors.
About Cellectis
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
See Also
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
